Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0KX6E
|
|||
| Former ID |
DNCL003480
|
|||
| Drug Name |
DI-Leu16-IL2
|
|||
| Drug Type |
Recombinant protein
|
|||
| Indication | Non-hodgkin lymphoma [ICD-11: 2B33.5; ICD-10: C85.9] | Phase 2 | [1] | |
| B-cell lymphoma [ICD-11: 2A86; ICD-10: C85.1; ICD-9: 202.8] | Phase 1/2 | [2] | ||
| Company |
Alopexx Oncology
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Leukocyte surface antigen Leu-16 (CD20) | Target Info | Modulator | [3] |
| KEGG Pathway | Hematopoietic cell lineage | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | ClinicalTrials.gov (NCT01874288) Phase I/II Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered Subcutaneously in Patients With B-cell NHL. U.S. National Institutes of Health. | |||
| REF 3 | National Cancer Institute Drug Dictionary (drug id 599668). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.